MedTrace Logo

Mixed Strain H. Pylori Infection in Patients Who Have Problems With Eradication of H. Pylori

NCT01164969 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2010-07-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether mixed H. pylori strain infection is the reason for eradication failure during treatment of H. pylori infection. The investigators present the results got from extensive sampling of biopsy samples taken from individuals diagnosed with H. pylori connected disease. The investigators were looking for individuals that were not able to eradicate H. pylori although they had susceptibility testing tailored antibiotic therapy. On their control visit after 2 months they presented again with H. pylori although at their first visit they had H. pylori isolated from biopsy sample sensitive to all antibiotics prescribed. Multi Locus Sequence Typing (MLST) was used to prove the sequence type of H. pylori and E test was used to determine susceptibility of H. pylori to antibiotics.

Conditions

  • H. Pylori Eradication Failure

Interventions

DRUG

Antibiotics to which H. pylori can not develope resistance

Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.

Sponsors & Collaborators

  • Institute of microbiology and immunology, Slovenia

    collaborator UNKNOWN

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Alojz Ihan, MD. PhD · Institute of mircobiology and immunology, Slovenia

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-12-31
Completion
2010-07-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01164969 on ClinicalTrials.gov